These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 6177716)

  • 1. Activation of protein C in vivo.
    Comp PC; Jacocks RM; Ferrell GL; Esmon CT
    J Clin Invest; 1982 Jul; 70(1):127-34. PubMed ID: 6177716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein C.
    Esmon CT
    Prog Hemost Thromb; 1984; 7():25-54. PubMed ID: 6099583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys.
    Colucci M; Stassen JM; Collen D
    J Clin Invest; 1984 Jul; 74(1):200-4. PubMed ID: 6547456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor: evidence for a protein-C-mediated mechanism.
    Colucci M; Triggiani R; Cavallo LG; Semeraro N
    Blood; 1989 Nov; 74(6):1976-82. PubMed ID: 2508792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of fibrinolytic activity by infusion of activated protein C into dogs.
    Comp PC; Esmon CT
    J Clin Invest; 1981 Nov; 68(5):1221-8. PubMed ID: 6895378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of succinylthrombin and its effects in vivo on the coagulation system.
    Nakagomi K; Yokota I; Ajisaka K
    Thromb Res; 1991 Jul; 63(1):111-21. PubMed ID: 1948815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C.
    Taylor FB; Hoogendoorn H; Chang AC; Peer G; Nesheim ME; Catlett R; Stump DC; Giles AR
    Blood; 1992 Apr; 79(7):1720-8. PubMed ID: 1558968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin-protein C interaction.
    Comp PC
    Nouv Rev Fr Hematol (1978); 1984; 26(4):239-42. PubMed ID: 6089102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model for thrombin protection against endotoxin.
    Taylor FB; Chang A; Hinshaw LB; Esmon CT; Archer LT; Beller BK
    Thromb Res; 1984 Oct; 36(2):177-85. PubMed ID: 6506035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
    Johnstone IB; Martin CA
    Can J Vet Res; 2000 Apr; 64(2):117-22. PubMed ID: 10805251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endothelial cells and vascular hemostasis].
    Levin EG; Hanano M
    Nihon Rinsho; 1992 Feb; 50(2):303-6. PubMed ID: 1319512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees.
    Levi M; ten Cate H; Bauer KA; van der Poll T; Edgington TS; Büller HR; van Deventer SJ; Hack CE; ten Cate JW; Rosenberg RD
    J Clin Invest; 1994 Jan; 93(1):114-20. PubMed ID: 8282778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
    Eisenberg PR; Siegel JE; Abendschein DR; Miletich JP
    J Clin Invest; 1993 May; 91(5):1877-83. PubMed ID: 8486759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
    Colucci M; Simioni P; Piro D; Prandoni P; Pagnan A; Semeraro N
    Haematologica; 2003 Dec; 88(12):1383-9. PubMed ID: 14687992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation.
    Giles AR; Nesheim ME; Mann KG
    J Clin Invest; 1984 Dec; 74(6):2219-25. PubMed ID: 6439744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
    Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
    Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.
    Petäjä J; Fernández JA; Gruber A; Griffin JH
    J Clin Invest; 1997 Jun; 99(11):2655-63. PubMed ID: 9169495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SSR182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity.
    Berry CN; Lassalle G; Lunven C; Altenburger JM; Guilbert F; Lalé A; Hérault JP; Lecoffre C; Pfersdorff C; Herbert JM; O'Connor SE
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1189-98. PubMed ID: 12438543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.
    Esmon CT; Owen WG
    Proc Natl Acad Sci U S A; 1981 Apr; 78(4):2249-52. PubMed ID: 7017729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
    Kruithof EK; Mestries JC; Gascon MP; Ythier A
    Thromb Haemost; 1997 May; 77(5):905-10. PubMed ID: 9184401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.